Johnson & Johnson (NYSE:JNJ) introduced that its single-shot Covid-19 vaccine was 66% efficient in stopping average and extreme instances of Covid-19 in its international part three trials. Efficacy assorted by area, with the shot proving 72% efficient within the U.S., 66% efficient in Lati www.nasdaq.com
Johnson & Johnson (NYSE:JNJ) introduced that its single-shot Covid-19 vaccine was 66% efficient in stopping average and extreme instances of Covid-19 in its international part three trials. Efficacy assorted by area, with the shot proving 72% efficient within the U.S., 66% efficient in Lati
www.nasdaq.com